A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (beta-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis

Trial Profile

A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (beta-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary) ; Dienogest
  • Indications Endometriosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 11 Sep 2017 Primary endpoint (Change of pelvic pain) has been met, according to the results published in the Fertility and Sterility.
    • 11 Sep 2017 Results published in the Fertility and Sterility
    • 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top